Overview

Assessing Response to Inhaled Prostacyclin With Hyperpolarized Xe MRI

Status:
Recruiting
Trial end date:
2022-02-01
Target enrollment:
Participant gender:
Summary
This study seeks to deploy several forms of 129Xe MRI contrast as well as emerging conventional proton MRI techniques for imaging lung structure and perfusion. Specifically, the 129Xe MRI scans will provide 3D images of ventilation and gas exchange, and spectroscopic indices will be evaluated too test gas exchange dynamics with high temporal resolution. The conventional 1H MRi scans will include a free-breathing ultra-short echo time scan that provides images similar to that of a CT scan. This will be done pre, immediately post, and 2-4 hours post inhaled prostacyclin therapy.
Phase:
Phase 2
Details
Lead Sponsor:
Bastiaan Driehuys
Collaborator:
United Therapeutics
Treatments:
Epoprostenol
Tezosentan
Xenon